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Abstract 
Tissue engineering is increasingly being recognized as a new approach that could alleviate the 
burden of tissue damage currently managed with transplants or synthetic devices. Making this 
novel approach available in the future for patients who would potentially benefit is largely 
dependent on understanding and addressing all those factors that impede the translation of this 
technology to the clinic. Cell-associated factors in particular raise many challenges, including 
those related to cell sources, up- and downstream techniques, preservation, and the creation of in 
vitro microenvironments that enable cells to grow and function as far as possible as they would 
in vivo. This paper highlights the main confounding issues associated with cells in tissue 
engineering and how these issues may hinder the advancement of therapeutic tissue engineering. 
Keywords: tissue engineering, cell manufacturing, tissue culture, clinical applications, stem 
cells. 
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1. Introduction 
Tissue engineering (TE) is based on the premise that by exploiting cellular biology, it should be 
possible to create a functional substitute analogous to the natural tissue or organ that can be used 
for replacement therapy. Thus, TE may hold the potential to address the transplantation crisis 
caused by the increasing demand for tissues that far outweighs the available supply (Fig. 1).1 
Since the advent of TE, remarkable progress has been achieved. However, many serious 
challenges still need to be addressed before this field can be exploited for widespread clinical 
applications. At the forefront of all challenges are those related to cells. As cells constitute the 
main pillar of TE strategies, whether the strategy is cell injection, cell induction, or cell-seeded 
scaffolds,2 tackling cell-associated problems is inescapable. 
To be effective for clinical purposes, cells should be easily procurable, scalable in vitro, and 
robust in culture and implantation. They should be obtained ethically and morally, be able to 
integrate functionally with the recipient tissue, and be non-immunogenic and safe; i.e., neither 
tumorigenic nor contaminated by any pathogen.3 In addition, cells should be capable of being 
processed for availability off the shelf, and stem cells should have the capability to differentiate 
to the desired lineage.4 
From the clinical perspective, obtaining cells that meet all these requirements for a particular 
therapeutic purpose presents a challenge. Consequently, only a handful of cytotherapeutic 
products are commercially available, in contrast to the considerable number of companies that 
are pursuing cell-based therapies.5 This paper will discuss the cell-linked problems that may arise 
at different stages of cell processing, from sourcing to implantation into the living body, and how 
these problems might deter the utilization of TE in clinical therapy. 
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2. Cell Source 
Cell acquisition represents a major hurdle that is linked with TE of every part of the body 
regardless of the tissue type or the strategy applied.6 For clinical applications, cell origins could 
be autogenic or allogenic – from the same patient or a different human donor, respectively. Each 
type can be further described in term of maturity: differentiated or stem cells.7 Every delineated 
type has potential drawbacks that could compromise its reliability (Fig. 2). 
Allogenic cells are donor-dependent and are associated with genetic mismatch and possible 
immune rejection, which would necessitate immunosuppressive therapy. Conversely, autogenic 
cells eliminate the need for potential donor matching and remove the immunological risk.4 
However, many hurdles offset the therapeutic benefits. Firstly, the harvesting biopsy may yield 
limited quantities of viable cells; in particular, this may be the case where the source is a 
diseased organ, such as when harvesting cells for TE of the liver from a patient with liver 
failure.8 Secondly, the target tissue may be inaccessible for direct biopsy, as in the case of the 
heart valve, or it may not be practical to biopsy at all, as with the spinal cord.9 Thirdly, timing 
limitations that involve weeks to months of in vitro culture to obtain an adequate number of cells 
may not always be practical, particularly in urgent or life-threatening conditions.10 Finally, the 
high production cost associated with patient-specific TE therapy compared with other treatments 
(even if they are less efficacious) can be a confounding factor when healthcare resources are 
limited.11 
In terms of maturity, all mature differentiated cells have a finite life span. Cell viability gradually 
declines until the growth is irreversibly arrested as the cells progress to senescence. This can 
provide a limited number of population doublings that may be insufficient to create a clinically 
relevant tissue.12 In contrast, stem cells – including adult stem cells (ASCs), embryonic stem 
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cells (ESCs) and induced pluripotent stem cells (iPSCs) – have a unique capacity for self-
renewal, potency and differentiation into various specialized cell types. However, this usefulness 
brings with it other problems.13 
ASCs are multipotent and have a finite potential for expansion. They are capable of generating 
the cell types of the pertinent tissue, but not all cell lineages.14 For instance, the proliferation and 
differentiation of mesenchymal stem cells (MSCs) to an osteogenic lineage are passage-
dependent. After the fourth passage, the alkaline phosphatase expression and calcium deposition 
are abrogated, the cell growth is impaired, and the doubling time is increased.15 In addition, the 
availability of MSCs is extremely limited; for example, the proportion of MSCs in the bone 
marrow is 1:100,000 nucleated cells.16 Furthermore, increased donor age has a negative impact 
on cell viability, proliferation and differentiation, with concomitant display of senescent features, 
when compared with cells isolated from a young donor.17,18 Moreover, spontaneous 
transformation of ASCs has been reported with 4–5 months’ cultivation, which raises a biosafety 
concern regarding cancer formation.19,20 
In contrast to ASCs, ESCs are indefinitely proliferative and pluripotent, i.e., they are able to 
differentiate to all tissue types.21 Therefore ESCs offer an unparalleled opportunity to circumvent 
the cell paucity that impedes tissue fabrication. However, the benefit of ESCs in TE could be 
seriously undermined by several complications. Firstly, the ethical and moral controversy 
surrounding the sacrifice of viable embryos to isolate ESCs.22,23 Secondly, the immunogenicity 
and potential rejection that can be triggered by immune-mismatched ESC-derived tissue. 
Grinnemo et al.24 state that ESCs are unlikely to be immune-compatible and postulate that this 
problem might be counteracted by altering the isolation method from immune to mechanical, and 
elimination of any ‘xeno’ products, including the feeder layers. However, it can be argued that 
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this immune incompatibility may not result merely from prolonged cell propagation in culture 
containing animal or synthetic constituents but, rather, from immune immaturity. The accelerated 
in vitro differentiation mechanism that recapitulates the long period of normal development 
within a short time span will cause a lack of immune inhibition ligands and retention of residual 
antigens within the differentiated cells that are eventually recognized as foreign antigens.25 The 
third hurdle relates to the identification of a cocktail of factors that drive the differentiation 
pathway to the desired lineage and optimize the differentiation efficiency, which with current 
isolation protocols does not yield a 100%-pure population. This incomplete differentiation poses 
a problem regarding culture heterogeneity, requiring an effective technique to purify the 
differentiated cells and prevent them from being contaminated by residual undifferentiated cells.4 
Failure in this regard will give rise to a further serious issue – i.e., the potential risk of 
tumorigenicity, namely benign teratoma or malignant teratocarcinoma.26,27 The reason for such 
propensity appears to be that stem and cancer cells share many cellular and signaling pathways.28 
In addition, aberrancy in the cultural environment adds another risk factor for triggering 
oncogenesis.29 According to Vacanti,3 cancer cells are originally derived from natural stem cells 
that, under severe disruption of their environmental cues, deviate from the normal repair process 
and shift to malignancy, resulting in uncontrolled multiplication without maturation. 
In an attempt to overcome problems associated with ESCs, iPSCs have been derived through cell 
reprogramming by delivering four transcription factors – Oct4, Sox2, Klf4 and c-Myc – that 
dedifferentiate the somatic cells and turn them back to the ESC-like state.30,31 iPSCs have been 
assumed to be as pluripotent as ESCs and are readily accessible and patient-specific. The ethical 
and immune issues associated with allogenic ESCs should therefore be eliminated.32 However, 
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the accumulative evidence has revealed that iPSCs may share many of the ESCs’ problems and, 
indeed, these may be greater.  
Compared with ESCs, iPSCs are more prone to tumorigenicity.27 This can be attributed to the 
multiple mutations with subsequent genetic and epigenetic instability,33 the imperfect induction 
process,34 and the reprogramming genes themselves that clearly demonstrate oncogenicity and 
overexpression in progressive and poorly prognostic tumours.35 Another challenging issue, 
contrary to what was expected, is that the autogenic iPSCs may provoke an immune response 
due to epigenetic modifications that can cause inappropriate gene and antigen expression.36 
Although the immunogenicity of iPSCs is not as intense as that of ESCs, this immune evasion 
may be problematic rather than advantageous because it might be exploited by engrafted aberrant 
cells and eventually result in tumor development.34 
Putting aside the obstacles stated above, the critical question that is still under debate is whether 
the iPSCs are truly equivalent to ESCs at a molecular and functional level.32 To date, there is no 
conclusive evidence proving that iPSCs are identical to ESCs. In fact, many studies have pointed 
out substantial differences between the two cell types and have shown that iPSCs retain the 
epigenetic memory of their source, an issue that may restrict the differentiation only into cell 
types of their original lineage.37,38 
3. Cell Manufacturing 
Once the cell source is secured, the next challenge to be considered relates to the processing 
stages of current Good Manufacturing Practice (cGMP), namely upstream processing 
(production of the desired cell quantity), downstream processing (harvesting and purification), 
and preservation.39 
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3.1. Upstream processing 
Whether the target application is for patient-specific (autologous) or for off-the-shelf (allogenic) 
therapy, scaling up of cells to approximately 107–1010 is necessary.5 Expansion of limited 
harvested cells to a clinically relevant quantity while preserving the fundamental quality 
parameters such as identity, genetic stability, purity, potency, and functionality is imperative for 
clinical therapy.39 Achieving this requires manufacturing technologies that are robust, scalable, 
predictable, economical, and compliant with cGMP.40 
A 2D static culture employing T-flasks or well plates is inconvenient when scaling up large 
quantities of monolayer cells due to the limited surface area/volume ratio. The use of a large 
number of culture vessels leads to real issues concerning high incubator occupancy, time, labor 
and media costs, as well as the contamination risk associated with the open culture system. In 
addition, the static environment permits gas exchange only at the liquid/gas interface (diffusion) 
and lacks the tight control of oxygen and nutrients.41 Furthermore, the production of large cell 
numbers requires frequent enzymatic passages that may lead to dedifferentiation of cells and 
elimination of the supportive extracellular matrix (ECM).42 
Roller bottles provide a greater surface area, and mechanical agitation prevents sedimentation of 
ingredients, however there is a lack of online monitoring and difficulty in handling large bottles 
manually.43 Automation and robotics may alleviate some of these issues by housing up to 90 x T-
175 culture flasks that produce approximately 2.5 x 109 cells, eliminating the manual effort and 
variability as well as minimizing the contamination risk. However, the high cost, static condition, 
and use of animal-derived products remain.44 
Bioreactor-based culture systems, by contrast, have evolved not only to mitigate the biological 
constraints in terms of providing a dynamic, sealed, automated, reproducible, tightly controlled 
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and strictly monitored environment, but also to apply mechanical and electrical stimulation.45 3D 
cell culture strategies such as self-aggregated spheroids, microcarriers and microencapsulated 
cells suspended in stirred or spinner vessels provide a potential strategy for stem cells expansion, 
although this can be at the expense of mass transfer and downstream processing. Central necrosis 
or unpredictable differentiation may arise due to a progressive decrease in oxygen and nutrients 
as the cell aggregates or microcarrier clumps increase in size. In addition, cell damage may be 
caused by the detrimental effects of hydrodynamic physical forces e.g. shear and perfusion. 
Moreover, it is difficult to maintain cell viability during cell cluster dissociation or cell-bead 
separation of aggregates and microcarriers, respectively. Microencapsulation may counteract 
agglomeration and excessive shear stress, however it shares similar mass transfer and 
decapsulation step limitations, as well as difficulties in visualization and issues of 
material/equipment cost.40,46 
3.2. Downstream processing 
The ability to undertake cell detachment from the culture surface without compromising the cell 
quality is as equally important as cell attachment and proliferation, particularly if the cells are 
intended for a clinical purpose. Cell harvesting requires development of large-scale enzymatic or 
mechanical dissociation technologies that gently decontaminate cells from any unwanted 
materials (e.g. carrier) with minimum hydrodynamic shear force.39 
Enzymatic digestion with trypsin is one of the most commonly used methods for cell recovery in 
2D culture and 3D microcarrier-based expansion systems.47,48 However, trypsin causes 
downregulation of growth- and metabolism-related proteins and upregulation of apoptosis-
related proteins.49 In addition, higher trypsin concentrations and longer incubation times are 
associated with damage to the structural integrity of cell surface integrins (adhesion proteins), 
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which subsequently reduces the cell’s adhesive ability.50 Furthermore, the vitality of cells 
cultured in scaffolds is also negatively affected by prolonged incubation in trypsin, which is 
necessary for ECM degradation. An increased trypsin incubation time not only releases more 
cells from the matrix, but also causes progressive cell destruction, which may be as high as 
35%.51 
Non-enzymatic harvesting has been suggested as a preferred alternative to avoid cell damage. 
Yang et al.52 demonstrated the possibility of using microcarriers coated with a thermo-responsive 
polymer to harvest MSCs and eliminate the need for enzymes. Following cell expansion on the 
microcarriers, the culture temperature was decreased to 32 °C and the cells were able to detach. 
However, this method involved the additional step of carrier coating with a polymer, which in 
turn may affect the original cell surface properties. In addition, it is particularly difficult to obtain 
an even polymer coating on scale-up.48 Cell conditioning with enzyme-free buffer is another 
method that has been utilized in place of trypsinization. However, it results in a significant 
reduction in cell viability and reattachment of dissociated cells.53 Mechanical dissociation of cell 
colonies by manual scraping has also been investigated and shown to be detrimental to cell 
viability and freeze-thaw survival rate when compared with trypsinization with gentle 
pipetting.54 
Recently, a novel microfluidic device has been designed by Qiu et al.55 to improve mechanical 
detachment and recovery of cells. This device works by shortening exposure of cells to enzymes 
and enables the use of non-enzymatic treatment such as the calcium chelator 
ethylenediaminetetraacetic acid (EDTA). Microfluidic dissociation augments cell separation with 
trypsin, resulting in a higher yield cell number (up to 93%) when compared with vortexing and 
pipetting. In addition, it can eliminate the enzymatic treatment when used with small cell clusters 
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or monolayer sheets. For more complex models, however, the combination of brief EDTA 
exposure followed by device processing is particularly useful as a non-enzymatic method. 
Nevertheless, optimization of this device to improve channel dimensions, flow rate, processing 
speed, prevent sample clogging, and facilitate milder enzymes remains to be reported. 
cGMP guidelines, particularly in terms of safety, make the above problems even more 
challenging to solve. The regulations imply that the bioprocessing should be automated, 
chemically-defined, economic, xeno-free, and pathogen-free. Any exposure to animal products 
such as a serum or feeder cell layer renders the cells irrelevant to clinical therapy.42 A further 
problem in the downstream stage is that the raw material itself is the final product i.e. cells, and 
thus cannot be terminally sterilized.56 
3.3. Cell preservation 
The difficulties in cell sourcing and expansion impose challenges in generating a robust 
preservation method to ensure a steady supply of high quality and well-characterized cell lines of 
various types. Bio-banking systems aim to cope with such demand, yet certain critical issues 
should be addressed, particularly cryopreservation and storage, in addition to the distribution, 
recording, tracking and database management. There are also issues in using a standardized 
protocol for cells that are different in source and require tailored culture conditions, passage 
number, and cryopreservation.57 
Cryopreservation normally utilizes controlled slow freezing (1–2 °C/min) and then rapid thawing 
with a cryoprotective agent, often 10% dimethyl sulfoxide (DMSO), to minimize the detrimental 
effects of ice recrystallization and cell shrinkage. However, it is still questionable whether this 
technique is convenient for banking and therapeutic applications. DMSO has a toxic effect that 
varies from cell type to cell type and is time-, temperature- and concentration-dependent.58 Its 
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clinical adverse effects, particularly with regard to the cardiovascular and respiratory systems, 
have been well documented.59 In addition, a systematic review of toxicity events linked to 
DMSO over the last two decades identified 779 adverse reactions, ranging from transient mild 
nausea or vomiting to more serious effects such as cardiac arrest, encephalopathy, respiratory 
stress, anaphylaxis or even death.60 Moreover, current washing protocols may not ensure 
complete elimination of DMSO, which can then result in different cell responses under similar 
conditions.61 Furthermore, the slow freezing protocols are not reliable for all cell types; e.g., the 
viability, functionality and potency of cryopreserved ESCs are significantly reduced in slow 
freezing, pushing the cells towards senescence and apoptosis.62-64 
Compared with conventional freeze–thawing, vitrification (ultra-rapid cooling without 
crystallization) demonstrates a higher cell recovery rate. The main drawbacks of this technique 
are again increased toxicity due to the high DMSO concentration required, increased 
contamination risk due to direct exposure of cells to liquid nitrogen, labor intensiveness, and 
inefficiency in large-scale cell production.63 One attempt to counter these problems is to use a 3D 
integrated expansion and cryopreservation strategy by microencapsulation of immobilized cells 
on microcarriers cultured in a stirred tank. In comparison with the non-encapsulated method, 
microencapsulation demonstrated cell recovery that was greater than 70% following 
cryopreservation.65 High expansion ratios up to twenty-fold were evident and post-thawing cell 
survival improved up to three-fold; more importantly, cellular characteristics were not 
compromised. Although this strategy successfully preserved the ESCs and eliminated the need 
for feeder cells, it involved the extra steps of encapsulation, decapsulation, and cell separation 
from the microcarriers. 
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Cell storage requires stringent methodology and quality control testing to ensure that the cells 
remain viable, contamination-free, and maintain their original phenotype.57 Storage problems 
related to misidentified and cross-contaminated cell lines have been reported in 18–36% of 
repositories.66 Contamination with environmental and microbial organisms can happen despite 
the strict sterilization techniques. Mycoplasma infection, for instance, has a high incidence rate, 
affecting approximately 5–30% of cell lines worldwide: it is particularly problematic, being 
resistant to antibiotics and visually undetectable.67 
Finally, cell shipping and delivery requires a strict time frame as cellular products have a limited 
shelf life, usually less than a few days. Therefore, it is essential to develop an efficient delivery 
system as well as simple qualitative assays to detect expiration of the cells.68 
4. Functional characteristics of cells 
In vivo, cells are integrated into a highly sophisticated matrix environment in which their 
function and response is not discrete from their surroundings.4,69 Therefore, functional 
characterization of cells in vitro to achieve the desired behavior poses a significant challenge 
(Fig. 3). 
The inter-relationship between structure and function means that cells will not function as 
efficiently in vitro as they function in vivo, unless a 3D architectural microenvironment 
analogous to that of the natural state is appropriately designed. In vivo, the local 
microenvironment is made up of an orchestrated and synergistic symphony of signals including 
cell–cell contact and cell–ECM interaction, as well as biomechanical and physical forces. These 
interrelated factors determine cell behavior interdependently rather than individually.70 This 
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issue is particularly significant for stem cells because any interruption in cells’ contact with their 
specific niche cues will not only affect the cells’ function but also their commitment and fate.71 
Another question to answer is to what extent the imitation of such intricate biological system is 
attainable in vitro. Cell–cell contact, for instance, is mediated in vivo by different extracellular 
molecules, namely endocrine signals (via the systemic vasculature), autocrine signals 
(generated and bound to the secretory cell), and paracrine signals (diffused from the adjacent 
cells). The latter is either homocrine (the signaling and responding cells are of the same type) or 
heterocrine (the signaling and responding cells are of different types). In vitro by contrast, only 
autocrine and homocrine signaling usually occur (Fig. 4).12 
In the natural environment, the ECM composition and architecture affect the reciprocal cell–
matrix interactions that elucidate a cascade of intracellular events influencing cell survival, 
proliferation, and protein synthesis. Failure to recapitulate the ECM function which exceeds the 
mechanical support will result in a passive cell–matrix interface fails to trigger such events and 
deprives cells of the substantial benefits of ECM that may alter cell phenotype.4 Unlike the 
ECM, the synthetic scaffold (which represents the artificial analogue to the authentic ECM) may 
lack this informative role and be unable to transmit growth cues due to the lack of functional 
binding ligands (domains) that cells can recognize and with which they can interact.  
In addition to the biological effect, the chemical, mechanical, electrical, topographical and mass 
transport properties need to be well adjusted to maintain a homeostatic balance. For example, 
increased porosity is essential for mass transport and elimination of central cell necrosis; 
however, this should not be at the expense of sacrificing mechanical integrity.72 
Equally important is increasing the surface area and cell concentration without compromising 
cell viability by mass transfer limitations. Oxygen transport is linked to its concentration, which 
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is ~220 µM in fully-oxygenated culture medium, compared with 8699 µM in oxyhemoglobin. 
The low oxygen concentration in media limits diffusion to the outer cell rim and deprives the 
core cells of oxygen and nutritional supply.73 As the cells dependent on oxygen diffusion cannot 
survive at a distance greater than 100–200 µm, considerable cell death in the scaffold’s deep 
areas will occur.74 In addition, once the cells start to secrete their ECM, another diffusion barrier 
is formed by the matrix components such as proteins and proteoglycans, which are relatively 
larger molecules with low diffusion coefficients; this may further hinder nutrient diffusion.75,76 
Cell death due to hypoxia will arise in vivo following implantation because the available oxygen 
is consumed by implanted cells within hours, while the angiogenesis process takes several days 
to form new capillary plexuses.7 
5. Conclusion 
Despite the significant advances witnessed by TE in the past few years, many challenges still lie 
ahead. At the heart of all obstacles are those related to the cells themselves, which constitute a 
major hurdle for the clinical application of engineered tissue equivalents. Cell sourcing, 
bioprocessing, shipping, marketing, delivery, and reconstruction of the cell microenvironment 
are sensitive procedures that have a significant impact on cells. Creating an optimal 
microenvironment for the cells appears to be the most challenging step in tissue engineering for 
clinical applications. Potential solutions rely partly on a better understanding of the cellular and 
molecular mechanisms that govern tissue regeneration in vivo, and partly on the ability to 
identify reliable strategies to enable us to mimic the in vivo environment and translate the in vitro 
system into clinical application. 
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Figure Captions 
Fig. 1 Increasing number of people on the organ transplant waiting list, compared with the 
stagnant donation and transplantation rates in the US. 
Fig. 2 The different categories of cells used in TE and their limitations. 
Fig. 3 The influencing factors on cells and their impact in determining the cell behavior. Cells 
perceive, read, interpret and respond to diverse external stimuli; in many cases the 
output determines the prospective inputs. 
Fig. 4 The four different biomolecule signals affecting cell behavior in vivo. 
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